Thousands of years before any of that
Cannabis has been used by humans for at least 5,000 years, and likely longer — archaeological evidence includes hemp fiber cordage dating back roughly 10,000 years, and burnt cannabis residue with unusually high psychoactive potency found in wooden braziers at a roughly 2,500-year-old cemetery in the Pamir Mountains, suggesting deliberate ceremonial use of a cultivated, more potent strain rather than accidental exposure. The plant spread through India, where it holds a specific religious association with Shiva and remains used in traditional preparations like bhang, and through the Islamic world as hashish, well before it became a subject of American drug policy at all.
A ban built substantially on who was using it, not what it did
Cannabis use in the early 20th-century United States became associated in the public imagination with Mexican immigrants and, separately, with Black jazz culture — associations that Anslinger's campaign leaned on directly and explicitly to build political support for prohibition, a pattern of racialized drug policy that recurs across this category's history (see also this category's piece on opium). The Marihuana Tax Act of 1937 made cultivation and possession effectively illegal nationwide; the Controlled Substances Act of 1970 later placed it in Schedule I, the most restrictive federal category, alongside heroin and LSD — a classification legally asserting no accepted medical use, despite a documented history of exactly that use dating back millennia.
The reversal, state by state
California's Proposition 215 in 1996 made it the first U.S. state to legalize medical cannabis; Colorado and Washington became the first to legalize recreational adult use in 2012. As of October 2026, 24 states plus Washington, D.C. have legalized recreational adult use (no state has been added since 2023), and roughly 40 states allow some form of medical cannabis. Federally, a December 2025 executive order led the DEA, in April 2026, to move FDA-approved marijuana products and state-licensed medical marijuana to the less restrictive Schedule III; all other cannabis, including recreational adult-use products, remains Schedule I while a broader rescheduling proceeding continues. The gap between state legality and federal scheduling remains a real, unresolved tension: it affects everything from banking access for dispensaries to whether cannabis businesses can take standard federal tax deductions.
What's genuinely changed about the product itself
One honest, important fact often missing from the legalization conversation: modern cannabis is, on average, considerably more potent than the cannabis of the 1960s-80s counterculture era — a well-documented trend across cultivation research and industry data, driven by decades of selective breeding for higher THC content, and further amplified by the now-widespread availability of concentrated products (extracts, vapes, "dabs") with far higher THC concentrations than flower alone. This matters directly for the risk section below, since several of cannabis's real risks scale with potency and frequency, not just with use itself.
The real dangers
No established fatal overdose from THC toxicity alone — this genuinely distinguishes cannabis from most other drugs in this category, and it's real and worth stating plainly.
Cannabis Use Disorder is real, not a myth. Somewhere between roughly 9% and 30% of regular users develop a genuine dependence, with risk substantially higher for people who start in adolescence and for daily or near-daily users — "cannabis isn't addictive" is an oversimplification that doesn't hold up against the clinical evidence.
Psychosis risk, particularly with high-potency products and adolescent use. This is the single most serious, well-established risk associated with modern cannabis: regular use of high-THC products, especially starting in adolescence and especially in people with a personal or family history of psychosis, is associated with a meaningfully increased risk of developing psychosis or schizophrenia. This isn't a fringe concern — it's one of the most consistently replicated findings in cannabis research, and it's specifically amplified by the rising potency described above.
Adolescent brain development. The brain's frontal cortex continues developing into the mid-20s, and regular cannabis use during this window is associated with measurable effects on attention, memory, and learning that are less pronounced in adult-onset users.
Edible-specific overconsumption risk. Edibles take considerably longer to produce effects than smoking or vaping (often 30–90 minutes), which leads many users to consume more before feeling anything, then experience an overwhelming, prolonged effect once it finally hits — a genuinely common, avoidable bad experience, and also a real poisoning risk for children who mistake THC edibles for ordinary candy.
Cannabinoid Hyperemesis Syndrome. An increasingly recognized condition in chronic, long-term heavy users: cyclic, severe vomiting that — counterintuitively — is often relieved specifically by hot showers, and resolves with sustained abstinence.
"Weed is basically harmless" and "weed causes schizophrenia" are both oversimplifications of the same real, more specific finding: risk concentrates heavily in high-potency products, adolescent use, and people with a personal or family history of psychosis — not in occasional adult use of moderate-potency products.
The genuine medical case
Unlike several other drugs in this category, cannabis has real, reasonably well-established medical value: effective treatment for chronic pain, chemotherapy-induced nausea and vomiting, and muscle spasticity in multiple sclerosis are among its better-evidenced uses. A CBD-based cannabis medication (Epidiolex) is FDA-approved specifically for certain severe, treatment-resistant childhood epilepsy syndromes. Evidence for anxiety and sleep is more mixed — some users report real benefit, while regular use can also worsen anxiety in others, and the direction of effect appears to depend significantly on the individual and the specific product used.
Try this
If you use cannabis products, check the THC percentage on the label (in legal markets, it's required) and compare it mentally to the roughly 2–4% potency typical of cannabis a few decades ago — the difference is a genuinely useful frame for understanding why "the same drug I used in college" may not be an accurate comparison anymore.
The takeaway
Cannabis has been used by humans for thousands of years, was banned in the U.S. substantially due to racialized political campaigning in the 1930s, and has reversed course dramatically in recent decades — now recreationally legal in 24 U.S. states while remaining federally Schedule I, with reclassification to Schedule III proposed but not yet completed. Modern cannabis is considerably more potent than historical cannabis, which matters directly for its most serious real risk: psychosis, particularly with high-potency products, adolescent use, and a personal or family history of psychosis. It also has genuine, well-evidenced medical value for chronic pain, chemotherapy-related nausea, and specific severe epilepsy syndromes.
Try this: check the THC percentage on any cannabis product you use and compare it to historical potency levels — it changes how "the same drug people always used" should actually be understood today.
Sources & Further Reading
Sources
- Ancient and ceremonial cannabis use, including the Pamir Mountains brazier findings, reflects published archaeological research.
- The 1937 Marihuana Tax Act, Harry Anslinger's campaign, and their documented racialized framing reflect published U.S. drug-policy history.
- Current state legalization status reflects Marijuana Policy Project and Pew Research Center tallies. Federal status: Executive Order of 18 December 2025; DEA final order, Federal Register, 28 April 2026 (2026-08176), rescheduling FDA-approved and state-licensed medical marijuana to Schedule III; Morgan Lewis, "Post–DEA Hearing, Broader Marijuana Rescheduling Questions Remain" (September 2026).
- Cannabis Use Disorder prevalence, psychosis risk research, and adolescent brain development findings reflect published clinical and epidemiological research.
- Medical cannabis evidence (chronic pain, chemotherapy-induced nausea, Epidiolex for epilepsy) reflects standard clinical and FDA documentation.
Go deeper
- 🌐 Search "cannabis potency THC increase decades research" for the trend data behind this piece's potency discussion
- 🌐 Search "cannabis psychosis risk adolescent research" for the clinical literature behind this piece's most serious risk finding
- 🌐 Related piece in this library: Opium, this category, for a parallel case of racialized U.S. drug-policy history